– ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated – ION449 demonstrated potential best-in-class efficacy profile for a self-administered subcutaneous monthly dose regimen – Study findings warrant further clinical development
Read more